Table 1.

Randomized or completed baseline characteristics of postmenopausal women with osteoporosis treated with Intravenous zoledronic acid 5 mg or placebo

Characteristic		ZOL group	Placebo group	P‐value
Age (years)	Randomized	57.22 ± 2.81	57.48 ± 3.18	0.482
	Completed	57.11 ± 2.75	57.12 ± 3.16	0.987
Height (cm)	Randomized	159.91 ± 5.99	159.70 ± 5.55	0.771
	Completed	164.01 ± 5.91	160.05 ± 5.71	0.957
Weight (kg)	Randomized	59.31 ± 2.64	58.77 ± 2.56	0.087
	Completed	59.27 ± 2.61	58.95 ± 2.58	0.344
Body‐mass index (kg/m2)	Randomized	22.65 ± 1.90	23.07 ± 2.17	0.840
	Completed	21.82 ± 1.08	21.58 ± 0.96	0.077
Years since natural menopause (years)	Randomized	9.73 ± 1.43	10.07 ± 1.52	0.090
	Completed	9.78 ± 1.45	9.98 ± 1.55	0.304
Alcohol consumption [Yes, cases (%)]	Randomized	35(22.6)	45(47.4)	0.053
	Completed	40(22.8)	45(40.9)	0.14
Serum t‐P1NP level (ng/mL)	Randomized	58.171 ± 8.367	59.459 ± 7.601	0.191
	Completed	58.489 ± 8.574	58.542 ± 7.781	0.961
Serum β‐CTX level (ng/mL)	Randomized	0.551 ± 0.095	0.545 ± 0.089	0.605
	Completed	0.534 ± 0.088	0.530 ± 0.078	0.668
Total hip BMD (g/cm2)	Randomized	0.759 ± 0.043	0.751 ± 0.042	0.085
	Completed	0.754 ± 0.042	0.748 ± 0.043	0.324
Posteroanterior spine BMD (g/cm2)	Randomized	0.636 ± 0.043	0.634 ± 0.044	0.759
	Completed	0.631 ± 0.041	0.628 ± 0.043	0.564

Subjects randomized: Zoledronic acid group, n = 175; placebo group, n = 110. Subjects completed: Zoledronic acid group, n = 155, placebo group, n = 95.

The data shown are for the postmenopausal women in the randomized and completed population. P‐values are for the two‐way comparisons and were determined by analysis of t‐test. The body‐mass index is the weight in kilograms divided by the square of the height in meters. Values are mean ± standard deviation or n (%). A two‐sample t‐test for continuous variables and Fisher exact test for categorical variables.

β‐CTX, C‐telopeptide of type I collagen; PINP, N‐terminal propeptide of type I collagen; ZOL, zoledronic acid.